A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Principal Investigator

Matthew Taylor

Study Purpose

This study is being done to test the safety and efficacy of TTI-621 in patients with solid tumors that can be punctured with a needle through the skin or in patients that have been diagnosed with mycosis fungoides (MF, a form of cutaneous T-cell lymphoma).

Medical Condition(s)

Mycosis fungoides (MF, a form of cutaneous T-cell lymphoma)
Solid tumor cancer

Eligibility Criteria

1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

Participants will receive the study drug for up to 4 injections as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. Participants will have scans collected 6, 12, and 18 weeks after the last dose of the study drug and a follow-up visit 30 days after the last dose of study drug. After the follow-up visit, participants will be contacted by phone every 3 months for 1 year.

Minors Included



Knight Clinical Trials Information Line


Trillium Therapeutics, Ltd.

Recruitment End


Compensation Provided


Go Back